DataZymes

DataZymes Inc provides data management and analytics solutions for healthcare organizations.

[DataZymes @DatazymesInc]

As #pharma companies adopt modern #marketingmixmodeling (MMM) tools, there could be IT integration, security, and compatibility issues. Learn more about such challenges in moving away from an FTE-based MMM in our blog. https://t.co/uG3R2x4ujr

[DataZymes @DatazymesInc]

With the increasing number of available datasets, #BI platforms for #pharma should be able to eliminate "white noise" to get to the relevant information and hidden patterns. https://t.co/TWNEZLY3JZ #commercialreporting

[DataZymes @DatazymesInc]

While pre-designed reporting solutions can prove to be immensely valuable for #SMBpharma, their business and analytics teams can benefit from a self-serve reporting and analytics solution https://t.co/iN0MULS5Z6 #commercialreporting

[DataZymes @DatazymesInc]

Over time, a tool-based #marketingmixmodel is becoming mainstream over a traditional FTE-based model in #pharma, with the importance of rapid experimentation and scientific modeling. https://t.co/uG3R2x4ujr

[DataZymes @DatazymesInc]

Modern #businessintelligence (BI) platform-based solutions offer the capability to design and develop a range of insights based on user personas such as field forces, brand teams, or executive leaders. #commercialreporting #smbpharma https://t.co/iN0MUM9GQE

[DataZymes @DatazymesInc]

A #BI platform should be able to cater to the needs of both #pharma sales representatives or brand teams looking to find answers to common questions, as well as power users who need the ability to deep dive into the data directly. https://t.co/TWNEZLY3JZ

[DataZymes @DatazymesInc]

To have a best-in-class #competitiveintelligence (CI) program, a #pharma organization needs to stay focused on the information that is most important to them, despite the high volume and diversity of data. https://t.co/XGJsJPFNvh

[DataZymes @DatazymesInc]

Modern #marketingmix tools for #pharma can be expensive and not match the dynamic needs of marketing teams, adding to overheads. Learn more about such challenges in our blog. https://t.co/uG3R2x4ujr

[DataZymes @DatazymesInc]

The nimble and lean organization structure of small #pharma companies can create a capacity challenge for purchasing secondary data, conducting in-depth market analytics (qualitative and quantitative), and running thorough modeling https://t.co/iN0MULS5Z6 #commercialreporting

[DataZymes @DatazymesInc]

In a highly competitive #pharma landscape, business users rightfully look for a #BusinessIntelligence system that’s flexible and agile to meet their future needs, both known and unknown. https://t.co/TWNEZLY3JZ

[DataZymes @DatazymesInc]

Delivering business value in #pharma with #analytics can only be done through a highly integrated, hybrid team structure. Download our guide to know more. https://t.co/WXQMqveOoB #commercialreporting

[DataZymes @DatazymesInc]

With #pharma being in the earlier stages of adopting new tools, most companies fear that the investment in new #marketingmixmodeling (MMM) tools can drain their resources without adding value. Learn more about such challenges in our blog. https://t.co/uG3R2x4ujr

[DataZymes @DatazymesInc]

Biopharma companies are now widely using the cloud, AI, data lakes, and wearables. However, organizations now can either decelerate the current pandemic pace of innovation or raise the bar even higher by accelerating the adoption of digital technologies https://t.co/hEjUfedcR3

[DataZymes @DatazymesInc]

Most SMBs in #pharma, being focused on specialized therapy areas such as rare diseases, immunology, etc., have to deal with disparate data sources with questionable quality and resulting data silos. Read on to know more #commercialreporting https://t.co/iN0MULS5Z6

[DataZymes @DatazymesInc]

While moving to a tool-based #marketingmixmodel (MMM) in #pharma, as most projects have data coming from multiple sources, any change in the data sources can cause the tool to break, leading to a major inconsistency. Learn more https://t.co/uG3R2x4ujr

[DataZymes @DatazymesInc]

The success of a #pharma #commercialreporting center of excellence (COE) depends on its collaborative work culture. The organizational structure should intrinsically support collaboration. Download our guide https://t.co/WXQMqveOoB

[DataZymes @DatazymesInc]

The key users of a #BusinessIntelligence platform in #pharma organizations are non-analysts from sales and marketing who are looking for valuable insights without spending too much time and effort digging for them. Read our blog to know more https://t.co/TWNEZLY3JZ

[DataZymes @DatazymesInc]

Marketing mix models (MMM) are expensive to run both in terms of effort and time, but with changing consumer behavior and data sources, brand managers may need to run their analysis more often than earlier. Know more https://t.co/uG3R2x4ujr

[DataZymes @DatazymesInc]

Small and emerging biotech companies are typically lean with teams structured by subject expertise, which often results in a heavy reliance on external service providers to support operations like analytics and data management. https://t.co/8BAyApdguw

[DataZymes @DatazymesInc]

To be successful in the growing segment of specialty pharmaceuticals, biopharma companies should determine how to work effectively with their specialty channel partners to build automated and secure data systems and next-generation analytics. https://t.co/Z3SI8Q0K2K